Adrenal Carcinoma Medication

1. Berruti A, Tiberio GAM, Sigala S. Adrenocortical Carcinoma. Cancers (Basel). 2021 Mar 3. 13 (5):[QxMD MEDLINE Link]. [Full Text].

2. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014 Apr. 35 (2):282-326. [QxMD MEDLINE Link]. [Full Text].

3. Kostiainen I, Hakaste L, Kejo P, Parviainen H, Laine T, Löyttyniemi E, et al. Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. Endocrine. 2019 Jul. 65 (1):166-174. [QxMD MEDLINE Link]. [Full Text].

4. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993 Dec 1. 72 (11):3145-55. [QxMD MEDLINE Link].

5. Sherlock M, Scarsbrook A, Abbas A, Fraser S, Limumpornpetch P, Dineen R, et al. Adrenal Incidentaloma. Endocr Rev. 2020 Dec 1. 41 (6):775-820. [QxMD MEDLINE Link]. [Full Text].

6. Rosai J. Adrenal gland and other paraganglia. Rosai and Ackerman’s Surgical Pathology. 10th ed. New York: Mosby Elsevier; 2011. 1067-1100.

7. Shiroky JS, Lerner-Ellis JP, Govindarajan A, Urbach DR, Devon KM. Characteristics of Adrenal Masses in Familial Adenomatous Polyposis. Dis Colon Rectum. 2018 Jun. 61 (6):679-685. [QxMD MEDLINE Link].

8. Kamilaris CDC, Hannah-Shmouni F, Stratakis CA. Adrenocortical tumorigenesis: Lessons from genetics. Best Pract Res Clin Endocrinol Metab. 2020 May. 34 (3):101428. [QxMD MEDLINE Link]. [Full Text].

9. Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004 Mar 1. 22(5):838-45. [QxMD MEDLINE Link].

10. Dehner LP, Hill DA. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors?. Pediatr Dev Pathol. 2009 Jul-Aug. 12(4):284-91. [QxMD MEDLINE Link].

11. Tritos NA, Cushing GW, Heatley G, Libertino JA. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. Am Surg. 2000 Jan. 66(1):73-9. [QxMD MEDLINE Link].

12. Shen XC, Gu CX, Qiu YQ, Du CJ, Fu YB, Wu JJ. Estrogen receptor expression in adrenocortical carcinoma. J Zhejiang Univ Sci B. 2009 Jan. 10(1):1-6. [QxMD MEDLINE Link]. [Full Text].

13. Kim Y, Margonis GA, Prescott JD, et al. Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surg. 2016 Apr. 151 (4):365-73. [QxMD MEDLINE Link]. [Full Text].

14. Chen QL, Su Z, Li YH, Ma HM, Chen HS, Du ML. Clinical characteristics of adrenocortical tumors in children. J Pediatr Endocrinol Metab. 2011. 24(7-8):535-41. [QxMD MEDLINE Link].

15. Shah NS, Lila A. Childhood Cushing disease: a challenge in diagnosis and management. Horm Res Paediatr. 2011. 76 Suppl 1:65-70. [QxMD MEDLINE Link].

16. Ribeiro J, Ribeiro RC, Fletcher BD. Imaging findings in pediatric adrenocortical carcinoma. Pediatr Radiol. 2000 Jan. 30 (1):45-51. [QxMD MEDLINE Link].

17. Bharwani N, Rockall AG, Sahdev A, Gueorguiev M, Drake W, Grossman AB, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol. 2011 Jun. 196 (6):W706-14. [QxMD MEDLINE Link]. [Full Text].

18. Angeli A, Osella G, Alì A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997. 47(4-6):279-83. [QxMD MEDLINE Link].

19. Schloetelburg W, Ebert I, Petritsch B, Weng AM, Dischinger U, Kircher S, et al. Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. Eur J Endocrinol. 2021 Dec 10. 186 (2):183-193. [QxMD MEDLINE Link]. [Full Text].

20. Bancos I, et al; ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020 Sep. 8 (9):773-781. [QxMD MEDLINE Link]. [Full Text].

21. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005 Feb. 90(2):871-7. [QxMD MEDLINE Link].

22. Williams AR, Hammer GD, Else T. Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. Eur J Endocrinol. 2014 Jun. 170(6):829-35. [QxMD MEDLINE Link].

23. Villelli NW, Jayanti MK, Zynger DL. Use and Usefulness of Adrenal Core Biopsies Without FNA or On-site Evaluation of Adequacy: A Study of 204 Cases for a 12-Year Period. Am J Clin Pathol. 2012 Jan. 137(1):124-31. [QxMD MEDLINE Link].

24. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009 Jun. 40(6):757-68. [QxMD MEDLINE Link].

25. Kiseljak-Vassiliades K, Bancos I, Hamrahian A, Habra M, Vaidya A, Levine AC, et al. American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach. Endocr Pract. 2020 Nov. 26 (11):1366-1383. [QxMD MEDLINE Link]. [Full Text].

26. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009 Jun. 16(2):573-83. [QxMD MEDLINE Link].

27. Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010 Oct. 95 (10):E161-71. [QxMD MEDLINE Link].

28. Duregon E, Molinaro L, Volante M, Ventura L, Righi L, Bolla S, et al. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Mod Pathol. 2014 Jan 17. [QxMD MEDLINE Link].

29. Adrenal Cortex. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Hoboken, NJ: Wiley-Blackwell; 2017. [Full Text].

30. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009 Jan 15. 115(2):243-50. [QxMD MEDLINE Link].

31. Kazaryan AM, Marangos IP, Rosseland AR, Røsok BI, Villanger O, Pinjo E, et al. Laparoscopic adrenalectomy: Norwegian single-center experience of 242 procedures. J Laparoendosc Adv Surg Tech A. 2009 Apr. 19(2):181-9. [QxMD MEDLINE Link].

32. Zografos GN, Vasiliadis G, Farfaras AN, Aggeli C, Digalakis M. Laparoscopic surgery for malignant adrenal tumors. JSLS. 2009 Apr-Jun. 13(2):196-202. [QxMD MEDLINE Link].

33. Kulis T, Knezevic N, Pekez M, Kastelan D, Grkovic M, Kastelan Z. Laparoscopic Adrenalectomy: Lessons Learned from 306 Cases. J Laparoendosc Adv Surg Tech A. 2011 Dec 13. [QxMD MEDLINE Link].

34. Agha A, Iesalnieks I, Hornung M, Phillip W, Schreyer A, Jung M, et al. Laparoscopic trans- and retroperitoneal adrenal surgery for large tumors. J Minim Access Surg. 2014 Apr. 10(2):57-61. [QxMD MEDLINE Link]. [Full Text].

35. Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2011 Dec 20. [QxMD MEDLINE Link].

36. Hermsen IG, Gelderblom H, Kievit J, Romijn JA, Haak HR. Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur J Endocrinol. 2008 Jun. 158(6):911-9. [QxMD MEDLINE Link].

37. Kemp CD, Ripley RT, Mathur A, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg. 2011 Oct. 92(4):1195-200. [QxMD MEDLINE Link].

38. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999 Dec. 6(8):719-26. [QxMD MEDLINE Link].

39. Corso CR, Acco A, Bach C, Bonatto SJR, de Figueiredo BC, de Souza LM. Pharmacological profile and effects of mitotane in adrenocortical carcinoma. Br J Clin Pharmacol. 2021 Jul. 87 (7):2698-2710. [QxMD MEDLINE Link]. [Full Text].

40. El Ghorayeb N, Rondeau G, Latour M, Cohade C, Olney H, Lacroix A, et al. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature. Medicine (Baltimore). 2016 Mar. 95 (13):e3180. [QxMD MEDLINE Link]. [Full Text].

41. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007 Jun 7. 356(23):2372-80. [QxMD MEDLINE Link].

42. Yongquan Tang 1 , Zhihong Liu 1 , Zijun Zou 1 , Jiayu Liang 1 , Yiping Lu 1 , Yuchun Zhu. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. Biomed International Research. June 4 2018. [QxMD MEDLINE Link]. [Full Text].

43. Postlewait LM, Ethun CG, Tran TB, et al. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. J Am Coll Surg. 2016 Apr. 222 (4):480-90. [QxMD MEDLINE Link]. [Full Text].

44. [Guideline] Neuroendocrine and Adrenal Tumors. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Version 1.2022 — May 23, 2022; Accessed: December 2, 2022.

45. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7. 366(23):2189-97. [QxMD MEDLINE Link].

46. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 Sep 18. 7 (1):253. [QxMD MEDLINE Link].

47. Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol. 2020 Jan 1. 38 (1):71-80. [QxMD MEDLINE Link].

48. Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013 Dec. 98 (12):4759-67. [QxMD MEDLINE Link]. [Full Text].

49. Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer. 2009 Sep. 16(3):907-18. [QxMD MEDLINE Link].

50. Hah JO. Intensive chemotherapy with autologous PBSCT for advanced adrenocortical carcinoma in a child. J Pediatr Hematol Oncol. 2008 Apr. 30(4):332-4. [QxMD MEDLINE Link].

51. Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009 Jul 1. 115(13):2816-23. [QxMD MEDLINE Link].

52. Thomas JJ, Tward JD. Stage Presentation, Care Patterns, Treatment Outcomes, and Impact of Radiotherapy on Overall Survival for Adrenocortical Carcinoma. Clin Genitourin Cancer. 2021 Oct. 19 (5):417-424. [QxMD MEDLINE Link].

53. [Guideline] Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018 Oct 1. 179 (4):G1-G46. [QxMD MEDLINE Link]. [Full Text].

54. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve Results Equal to Surgery Plus Mitotane. Ann Surg Oncol. 2009 Oct 23. [QxMD MEDLINE Link].

Bagi RP Jana, MD, MBA, MHA, FACP Professor of Cancer Medicine, MD Anderson Cancer Center; Professor of Medicine, University of Texas Medical Branch at Galveston

Bagi RP Jana, MD, MBA, MHA, FACP is a member of the following medical societies: American Cancer Society, American Medical Association, American Society of Clinical Oncology, SWOG

Disclosure: Nothing to disclose.

Kush Sachdeva, MD Southern Oncology and Hematology Associates, Inspira Health Network

Disclosure: Nothing to disclose.

Lawrence T Kim, MD, FACS, FACE Professor, Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, University of North Carolina at Chapel Hill School of Medicine; Member, UNC Lineberger Comprehensive Cancer Center

Lawrence T Kim, MD, FACS, FACE is a member of the following medical societies: American Association of Clinical Endocrinologists, American Association of Endocrine Surgeons, American College of Endocrinology, American College of Surgeons, American Thyroid Association, International Association of Endocrine Surgeons, Parkland Surgical Society, Society of Surgical Oncology, Southern Surgical Association, Surgical Discovery Club

Disclosure: Nothing to disclose.

Robert J Arceci, MD, PhD King Fahd Professor of Pediatric Oncology, Professor of Pediatrics, Oncology and the Cellular and Molecular Medicine Graduate Program, Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, and American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Timothy P Cripe, MD, PhD Professor of Pediatrics, Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center; Clinical Director, Musculoskeletal Tumor Program, Co-Medical Director, Office for Clinical and Translational Research, Cincinnati Children's Hospital Medical Center; Director of Pilot and Collaborative Clinical and Translational Studies Core, Center for Clinical and Translational Science and Training, University of Cincinnati College of Medicine

Timothy P Cripe, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Antonio Tito Fojo, MD Senior Clinical Investigator, Medicine Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health

Disclosure: Nothing to disclose.

Samuel Gross, MD Professor Emeritus, Department of Pediatrics, University of Florida; Clinical Professor, Department of Pediatrics, University of North Carolina; Adjunct Professor, Department of Pediatrics, Duke University

Samuel Gross, MD is a member of the following medical societies: American Association for Cancer Research, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Gabriel I Uwaifo, MD Associate Professor, Section of Endocrinology, Diabetes and Metabolism, Louisiana State University School of Medicine in New Orleans; Adjunct Professor, Joint Program on Diabetes, Endocrinology and Metabolism, Pennington Biomedical Research Center in Baton Rouge

Gabriel I Uwaifo, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, American Society of Hypertension, and The Endocrine Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lawrence C Wolfe, MD Senior Associate in Pediatric Hematology/Oncology, Schneider Children's Hospital

Lawrence C Wolfe, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Association of Blood Banks, American Society of Hematology, Children's Oncology Group, and Eastern Society for Pediatric Research

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article